MIKE LEDESMA: Open Payments
NPI 1306261599 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$782 in 44 payments from 16 companies in 2025. Trend: 2023 $1,713 · 2024 $1,622 · 2025 $782
Food & beverage: $782
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $234 |
| ABBVIE INC. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Lilly USA, LLC | 2 | $57 |
| Abbott Laboratories | 2 | $49 |
| Amgen Inc. | 2 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
| PFIZER INC. | 2 | $37 |
| SANOFI-AVENTIS U.S. LLC | 2 | $35 |
| GlaxoSmithKline, LLC. | 2 | $29 |
Products named: Ozempic, REXULTI, JARDIANCE, Wegovy, VRAYLAR, FREESTYLE LIBRE 3, TZIELD, MOUNJARO.
Industry payments across TX — which companies pay providers there.
